United Therapeutics presented data at CHEST 2026 showing ralinepag reduced clinical worsening risk in PAH and nebulized treprostinil reduced disease progression in IPF. FDA has accepted NDAs for both drugs.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
